Seribantumab

also known as MM-121 · SAR256212

Monoclonal antibody targets ERBB3 via inhibition

Developed for: non-small cell lung carcinoma · colorectal cancer · breast cancer · cancer · head and neck squamous cell carcinoma · Her2-receptor negative breast cancer · malignant pancreatic neoplasm · triple-negative breast carcinoma
+17 more
· adenocarcinoma · cholangiocarcinoma · esophageal cancer · fallopian tube cancer · gallbladder cancer · head and neck cancer · kidney cancer · lung cancer · malignant epithelial tumor of ovary · metastatic neoplasm · ovarian cancer · peritoneal neoplasm · peritoneum cancer · prostate cancer · sarcoma · urinary bladder cancer · uterine cancer
Investigated by: Merrimack Pharmaceuticals · Sanofi · Elevation Oncology · Ottawa Hospital Research Institute

Trials 14

today NCT04790695 · Ph 2 NCT04383210 · Ph 2 NCT03241810 · Ph 2 NCT02538627 · Ph 1 NCT02387216 · Ph 2 NCT01436565 · Ph 1 NCT01451632 · Ph 1 NCT01447706 · Ph 2 NCT01447225 · Ph 1 NCT01421472 · Ph 2 NCT01209195 · Ph 1 NCT01151046 · Ph 2 NCT00994123 · Ph 1/2 NCT00734305 · Ph 1

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT02538627	Aug 2015 → Oct 2016	colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma	Merrimack Pharmaceuticals	Terminated	No outcome recorded Stop: Business
Phase 1	NCT01436565	Nov 2011 → May 2014	—	Sanofi	Completed	No outcome recorded
Phase 1	NCT01451632	Oct 2011 → Nov 2013	colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma	Merrimack Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01447225	Oct 2011 → Nov 2013	cancer	Merrimack Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01209195	Oct 2010 → May 2014	Her2-receptor negative breast cancer, peritoneal neoplasm	Merrimack Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00734305	Jul 2008 → May 2010	cancer	Merrimack Pharmaceuticals	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00994123	Feb 2010 → Nov 2014	non-small cell lung carcinoma	Merrimack Pharmaceuticals	Completed	No outcome recorded
Phase 27 trials · 2 missed
Phase 2	NCT04790695	Mar → Dec 2021	malignant pancreatic neoplasm	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 2	NCT04383210	Sep 2020 → Feb 2024	breast cancer, cholangiocarcinoma, colorectal cancer, esophageal cancer +11	Elevation Oncology	Terminated	No outcome recorded Stop: Business
Phase 2	NCT03241810	Aug 2017 → Nov 2018	breast cancer	Elevation Oncology	Terminated	No outcome recorded Stop: Business
Phase 2	NCT02387216	Feb 2015 → Jan 2019	adenocarcinoma, non-small cell lung carcinoma	Elevation Oncology	Terminated	Missed primary
Phase 2	NCT01447706	Oct 2011 → Sep 2013	fallopian tube cancer, malignant epithelial tumor of ovary, peritoneum cancer	Merrimack Pharmaceuticals	Completed	Missed primary
Phase 2	NCT01421472	Aug 2011 → Dec 2013	triple-negative breast carcinoma	Merrimack Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01151046	Jun 2010 → Jun 2014	Her2-receptor negative breast cancer	Merrimack Pharmaceuticals	Completed	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

Field	Value	Cited text
Known as	seribantumab	“Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG)...” PMID 27998236 ↗ Oct 2016 3 NCT03241810 ↗ NCT04790695 ↗ NCT04383210 ↗
Known as	MM-121	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00994123 ↗ 10 NCT01451632 ↗ NCT00734305 ↗ NCT01151046 ↗ NCT01421472 ↗ NCT01447706 ↗ NCT01447225 ↗ NCT01436565 ↗ NCT02538627 ↗ NCT02387216 ↗ NCT01209195 ↗
Known as	SAR256212	“MM-121 (SAR256212) + exemestane” NCT01151046 ↗ 1 “MM-121 (SAR256212)” NCT01436565 ↗
Action	Inhibit	“to block heregulin (HRG/NRG)-mediated ErbB3 signaling and induce receptor downregulation” PMID 30975923 ↗ Apr 2019
Modality	Monoclonal antibody	“Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.” PMID 34250553 ↗ Jul 2021
Route	Intravenous	“MM-121 administered IV QW to determine MTD or RP2D + expansion cohort at MTD/RP2D” NCT00734305 ↗
Target	ERBB3	“binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block” PMID 30975923 ↗ Apr 2019